Previous data on CF students with the G551D mutation, treated with novel genetic CFTR modulator therapy, showed a significantly lower loss in school productivity and activity impairments compared to those patients, with the F508del mutation, who were managed using standard of care [21]. This evidence concerns the gene CFTR and cystic fibrosis.